About
Antibody, Immuno-oncology
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
462
By Phase
PHASE1/PHASE2: 2PHASE1: 5
By Status
RECRUITING: 3COMPLETED: 3TERMINATED: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07158918Lead Sponsor
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
PHASE1/PHASE2Recruiting
65 participants
Started: Aug 6, 2025 · Completed: Dec 2, 2027
NCT06126666Lead Sponsor
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
PHASE1Recruiting
96 participants
Started: Nov 7, 2023 · Completed: Nov 15, 2027
NCT05756920Lead Sponsor
This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants
PHASE1Completed
91 participants
Started: Dec 31, 2022 · Completed: Apr 30, 2025
NCT05101109Lead Sponsor
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
PHASE1Completed
24 participants
Started: Oct 6, 2021 · Completed: May 14, 2024
NCT04762641Lead Sponsor
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
PHASE1Recruiting
100 participants
Started: Apr 1, 2021 · Completed: Jun 15, 2026
Funding History (1)
D
Sep 7, 2023
Locations (1)
Headquarters
Seongnam, Korea
Map
Loading map...